Altered GABAB receptor sensitivity in heavy drinkers indexed using a TMS-based biomarker: a randomized controlled experimental medicine trial
Open Access
- 23 October 2026
- journal article
- research article
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1) , 582
Abstract
Metabotropic γ-aminobutyric acid type B receptors (GABA B Rs) are implicated in alcohol use disorder (AUD) and represent a promising therapeutic target. However, robust biomarkers of GABA B Rs target engagement and sensitivity in humans are lacking. We examined transcranial magnetic stimulation (TMS)–derived cortical inhibition and growth hormone (GH) release as measures of GABA B R function, and whether heavy alcohol use is associated with altered responses to pharmacological GABA B R activation. In a randomized, double-blind, placebo-controlled crossover study, 31 healthy volunteers (16 heavy drinkers, 15 light drinkers) received baclofen 30 mg, baclofen 60 mg, or placebo across three sessions. Long-interval intracortical inhibition (LICI), short-interval intracortical inhibition, and intracortical facilitation were assessed with paired-pulse TMS at baseline and ~60 min post-dose. Baclofen blood concentrations and plasma GH levels were measured. Baclofen produced dose-dependent increases in GH release, confirming neuroendocrine GABA B R engagement. The LICI response to baclofen differed between groups: In light drinkers, baclofen at 30 mg potentiated LICI, and a similar potentiation was seen at 60 mg, indicating that a plateau may have been reached. In contrast, in heavy drinkers, a potentiation of LICI similar to that in light drinkers was seen at 30 mg baclofen, but was absent at the 60 mg dose despite comparable pharmacokinetics, suggesting altered GABA B R function. Effects were selective for GABA B R–mediated inhibition, with no consistent modulation of short-interval intracortical inhibition or corticospinal excitability. Acute baclofen administration reveals altered GABA B R sensitivity in heavy drinkers, with preserved responses at lower doses but reduced response under stronger agonist stimulation. LICI and GH release provide complementary biomarkers of central and peripheral GABA B Rs engagement and may support translational development of mechanism-based treatments for AUD.Keywords
Funding Information
- Knut och Alice Wallenbergs Stiftelse (Clinical Scholar)
- Vetenskapsrådet (2024-02537)
This publication has 36 references indexed in Scilit:
- Choice of alcohol over a natural reward: an experimental study in light and heavy social drinkersPsychopharmacology, 2024
- Pharmacotherapy for Alcohol Use DisorderJAMA, 2023
- The GABAB receptor positive allosteric modulator ASP8062 reduces operant alcohol self-administration in male and female Sprague Dawley ratsPsychopharmacology, 2021
- GABAB Receptor Functions in the Mesolimbic Dopamine System2016
- Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient SettingsJAMA, 2014
- Prevalence, Correlates, Disability, and Comorbidity of DSM-IV Alcohol Abuse and Dependence in the United StatesArchives of General Psychiatry, 2007
- Mental Health Screening in Addiction, Corrections and Social Service Settings: Validating the MMSInternational Journal of Mental Health and Addiction, 2007
- The role of GABAB receptors in intracortical inhibition in the human motor cortexExperimental Brain Research, 2006
- Role of GABAB receptor in alcohol dependence: Reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholicsNeurotoxicity Research, 2004
- Growth hormone response to baclofen: a comparison of 10-mg and 20-mg doses in healthy menPsychiatry Research, 1996